SUNNYVALE, Calif. and
NEW YORK, June 27, 2017 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) and Montefiore Einstein Center for
Cancer Care (MECCC), part of the Montefiore Health System (MHS),
announced today that Montefiore doctors have treated the first
cancer patients in New York with
the advanced Radixact™ Treatment Delivery System. The system
was designed to deliver image-guided intensity-modulated (IG-IMRT)
radiation therapy, an extremely precise form of radiation therapy.
Montefiore is the only hospital in New
York State, and in the greater New
York area, to have this equipment.
The Radixact System is the next generation
TomoTherapy® platform developed to enable doctors to
more efficiently and effectively deliver precise radiation
treatments to more patients with cancer every day. What makes the
Radixact technology different from conventional radiation systems
is the integration of a CT scanner with the radiation therapy
delivery system. The built-in CT scanner performs daily imaging
before each treatment session to determine the shape and position
of the tumor. This allows for accurate and precise tumor targeting,
while reducing the radiation dose to normal, healthy tissue. Only
then, is radiation delivered from 360 degrees around the patient's
body allowing for treatment of any target, irrespective of its
length.
Daily pretreatment imaging, coupled with the System's Accuray
Precision™ Treatment Planning System and PreciseART™ Adaptive
Radiation Therapy software, informs precise treatment planning and
mid-course decision-making, so clinical teams can instantly adapt
therapy to:
- Changes in tumor size, shape and location
- Subtle changes in the location of organs and other healthy
tissue, due to weight gain or loss
Identifying and correcting for any variations in patient
positioning, as well as biological changes, ensures the continued
precision and safe delivery of the radiation dose to the target
area, resulting in fewer long term side effects.
The Radixact System is capable of treating all standard
radiation therapy indications including breast, head and neck,
lung, and prostate cancers, in addition to complex treatments such
as total marrow irradiation. The Montefiore patients were
treated for prostate cancer and plans are also in place to use the
System for patients with Ob/Gyn related cancers and head and neck
cancers, as these often require alterations to therapy mid-course
due to changes in tumor size, location and individual weight.
See a video of the System and its unique benefits here:
https://youtu.be/vMTRm3qObeU
"We could not be more thrilled to have this amazing technology
here at Montefiore, along with the clinical expertise to guide its
use," said Shalom Kalnicki,
M.D., F.A.C.R.O., professor and chair, Department of Radiation
Oncology, Montefiore Einstein Center for Cancer Care and
Albert Einstein College of Medicine.
"We know the ability to adapt the radiation dose to the actual
target and normal tissue position and shape is key to the future of
radiation therapy. This technology is so sophisticated it can
streamline treatment so cures are more frequent and patients are
better protected from side effects they have suffered in the
past. The Radixact System is an exciting step forward
solidifying the Montefiore Einstein Center for Cancer Care's place
on the frontier of cancer treatment."
According to the Centers for Disease Control and Prevention
(CDC), the state of New York has
the third highest cancer rate in the
United States.1 More than 105,000 people in
New York are diagnosed with cancer
each year, or approximately 287 people each day.2
Innovations such as the Radixact System are helping to make it
possible for people who are diagnosed with cancer to live longer
with a better quality of life than was previously possible.
"Montefiore is a leading Academic Medical Center known around
the world for its innovate cancer research and care," said
Josh Levine, President and Chief
Executive Officer of Accuray. "We are proud that they selected the
innovative Radixact System to enhance the range of treatment
options they provide to their patients. The Montefiore team's early
experience with the system has been exceedingly positive, similar
to what we are hearing from other physicians, and reinforces the
value it can bring to a radiation oncology department by improving
the effectiveness and efficiency with which radiation treatments
can be delivered."
Important Safety Information
For Important Safety
Information please refer to
http://www.accuray.com/safety-statement
About Montefiore Health System
Montefiore Health System is one of New
York's premier academic health systems and is a recognized
leader in providing exceptional quality and personalized,
accountable care to approximately three million people in
communities across the Bronx, Westchester and
the Hudson Valley. It is comprised of 11 hospitals, including
the Children's Hospital at Montefiore, Burke Rehabilitation
Hospital and close to 200 outpatient care sites. The advanced
clinical and translational research at its medical
school, Albert Einstein College of Medicine, directly
informs patient care and improves outcomes. From the
Montefiore-Einstein Centers of Excellence in cancer, cardiology and
vascular care, pediatrics, and transplantation, to its preeminent
school-based health program, Montefiore is a fully integrated
healthcare delivery system providing coordinated, comprehensive
care to patients and their families. For more information please
visit www.montefiore.org. Follow us on Twitter and
view us on Facebook and YouTube
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a
radiation oncology company that develops, manufactures and sells
precise, innovative tumor treatment solutions that set the standard
of care with the aim of helping patients live longer, better lives.
The company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments. For more
information, please visit www.accuray.com
Safe Harbor Statement
Statements made in this press
release that are not statements of historical fact are
forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are
not limited, to advantages of new technology, clinical
applications, clinical results, successful adoption of new
technologies, patient experiences and outcomes, and Accuray's
leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Accuray Media Contacts
Beth
Kaplan
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
Jane Hauser
MSL Group
+1 (781) 684-0770
accuray@mslgroup.com
Accuray Investor Contact
Doug Sherk
Investor Relations, EVC Group
+1 (415) 652-9100
dsherk@evcgroup.com
Montefiore Health System Media Contact
Elizabeth Kaledin
Montefiore
718-920-8173
ekaledin@montefiore.org
1https://www.cdc.gov/cancer/dcpc/data/state.htm
accessed on April 25, 2017
2https://statecancerprofiles.cancer.gov/incidencerates/index.php?stateFIPS=36&cancer=001&race=00&sex=0&age=001&type=incd&sortVariableName=rate&sortOrder=default#results
accessed on April 26, 2017
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/montefiore-is-first-in-ny-metropolitan-area-to-treat-cancer-patients-with-accuray-radixact-system-300479908.html
SOURCE Accuray Incorporated